ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1207

Novel Role of Liver X Receptor Alpha (LXRα) in the Attenuation of TLR Signalling: Implications in Congenital Heart Block

Susmita Bagchi1, Mark Halushka2, Robert M. Clancy1 and Jill P. Buyon1, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: metabolism and toll-like receptors, NFB

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Signaling Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Anti-SSA/Ro associated congenital heart block provides a unique opportunity to examine the effector arm of immunity and define the molecular mechanisms that link maternal antibodies and the inflammatory cellular response. Based on an agnostic survey of transcripts from macrophages stimulated by immune complexes (IC) containing anti-Ro, 60kD Ro, and ssRNA-hY3, risk and protective genes were recently compiled. Two highly significant candidates in the injury spectrum, one enhancing – interleukin 6 (IL6), and one attenuating – liver X receptor alpha (NR1H3 or LXRα), which has been shown to decrease NFkB-induced expression, were identified.  Accordingly, this study was initiated to determine the potential functional significance of these candidates; specifically, whether LXRα expression influences TLR7/8 ligation and downstream NF-kB–dependent cytokine release underlying both overt inflammation and the transition to established fibrosis.   

Methods: The approach included both in vitro and in vivo studies. The former employed TLR7/8 stimulated human macrophage cells (THP1) and peripheral blood macrophages in the presence and absence of a LXRα ligand, and the latter used immunohistochemistry of autopsy tissue from the heart of a fetus dying with CHB and an age matched control. 

Results: As expected, exposure of THP-1 cells and isolated macrophages to a LXRα ligand, GW3965 (10 μM), resulted in the upregulation of its receptor LXRα mRNA (10±1.25 vs 1, N=4).  In addition, LXRα expression was likewise increased in hY3-transfected macrophages (14±6.1 vs 1), confirming results obtained by the previous microarray data (gene name NR1H3). Increased protein expression of LXRα following either GW3965 or hY3 alone was confirmed using anti-LXRα antibodies in immunofluorescence and permeabilized FACS (whole cells, digitonin treated, respectively). To identify whether an increase of LXRα expression might alter proinflammatory hY3-induced transcripts, macrophages were simultaneously treated with hY3 and GW3965.  As expected, hY3 treatment increased IL-6 mRNA expression compared to untreated cells or those treated with GW3965 alone (transcript normalized to GAPDH, 2.04, 1.03 and 0.83, respectively).  In a cotreatment approach, we addressed whether the provision of ligand and upregulation of its receptor would impact the hY3-stimulated expression of IL-6. There was a 65% reduction in IL6 transcripts in macrophages treated with hY3 and GW3965 compared to hY3 alone (N=2) suggesting that ligand binding to receptor (but not increase of receptor alone) is a sufficient stimulus to trigger a sustained anti-inflammatory response.  Immunohistochemistry of a heart from a fetus dying with CHB revealed focal expression of LXRα in proximity to the AV nodal region in areas containing calcified myocytes.  In contrast, as assessed in the control heart, healthy myocytes did not express LXRα. 

Conclusion: These data support the novel identification of a link between TLR7 activation and expression of a potential anti-inflammatory checkpoint, LXRα. In vitro and in vivo approaches suggest that LXRα may represent a thwarted attempt to forestall a smoldering hY3-driven inflammatory milieu.


Disclosure:

S. Bagchi,
None;

M. Halushka,
None;

R. M. Clancy,
None;

J. P. Buyon,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-role-of-liver-x-receptor-alpha-lxr%ce%b1-in-the-attenuation-of-tlr-signalling-implications-in-congenital-heart-block/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology